Roadmap for the development of candidate vaccines for FMD

What are we trying to achieve and why? What is the problem we are trying to solve?

The development of safe vectors to be used for producing safe, effective, cross-reacting DIVA vaccines for FMD

What are the scientific and technological challenges (knowledge gaps needing to be addressed)?

• Prevent the development of immune responses to the vector
• Ensure the expression of the protective antigens by a replicating organism with the development of VN-Abs and
  CTC responses
• Create stable genetically modified organisms expressing the desired FMD antigens
• Identify the Ag combination to give widest protection against the various field isolates

What approaches could/should be taken to address the research question?

• Generation of genetically modifies organisms (viruses or bacteria) expressing the protective antigens of different
  FMDV strains
• Incorporation of molecular adjuvants

What else needs to be done before we can solve this need?

Identity of protective antigens

Existing knowledge including successes and failures

Replication-defective human adenovirus type 5 (Ad5) vectors that contain the capsid-encoding regions of FMD virus
(FMDV) are currently used and are promising in terms of efficacy, cross reaction and safety.